Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Gomez

Showing results (141-150 of 144) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 144 results.
Lancet Regional Health. Americas|May 7, 2026
Ten-year subtype survival and systemic-therapy pathways analysis after breast-cancer recurrence in the LACRN MPBC multicountry cohort studyJavier Retamales, Ingiborg Araya, Eliana Abdelhay, et al.
NPJ Precision Oncology|March 14, 2026
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancerPaolo Tarantino, Se-Eun Kim, Melissa E Hughes, et al.
Cancer Biomarkers : Section a of Disease Markers|July 28, 2007
Workshop on imaging science development for cancer prevention and preemptionGary J Kelloff, Daniel C Sullivan, Houston Baker, et al.
JCO Global Oncology|May 9, 2024
Implementing Standard Diagnosis and Treatment for Locally Advanced Breast Cancer Through Global Research in Latin America: Results From a Multicountry Pragmatic TrialJavier Retamales, Adrián Daneri-Navarro, Nora Artagaveytia, et al.
Pageof 15

Showing results (141-150 of 144) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 144 results.
Lancet Regional Health. Americas|May 7, 2026
Ten-year subtype survival and systemic-therapy pathways analysis after breast-cancer recurrence in the LACRN MPBC multicountry cohort studyJavier Retamales, Ingiborg Araya, Eliana Abdelhay, et al.
NPJ Precision Oncology|March 14, 2026
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancerPaolo Tarantino, Se-Eun Kim, Melissa E Hughes, et al.
Cancer Biomarkers : Section a of Disease Markers|July 28, 2007
Workshop on imaging science development for cancer prevention and preemptionGary J Kelloff, Daniel C Sullivan, Houston Baker, et al.
JCO Global Oncology|May 9, 2024
Implementing Standard Diagnosis and Treatment for Locally Advanced Breast Cancer Through Global Research in Latin America: Results From a Multicountry Pragmatic TrialJavier Retamales, Adrián Daneri-Navarro, Nora Artagaveytia, et al.
Pageof 15